Mirati Therapeutics, Inc.

How this insider trader nailed every single stock trade

How this insider trader nailed every single stock trade

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Cramer names biopharma companies to watch as industry mergers start to pile up

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

Mirati's lung cancer drug gets EU's regulatory backing

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Bristol-Myers Squibb Acquisition Of Mirati Makes Sense

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus

MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX

Analysts Target Biotech Name on Buyout Buzz

Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics

Bristol-Myers Squibb Buys Mirati Therapeutics to Boost Cancer Drug Portfolio

Bristol Myers Squibb to buy cancer drugmaker Mirati Therapeutics in up to $5.8B deal